192 related articles for article (PubMed ID: 32905759)
21. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
Pettit RS
Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
[TBL] [Abstract][Full Text] [Related]
22. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
23. Distribution of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutations in a Cohort of Patients Residing in Palestine.
Siryani I; Jama M; Rumman N; Marzouqa H; Kannan M; Lyon E; Hindiyeh M
PLoS One; 2015; 10(7):e0133890. PubMed ID: 26208274
[TBL] [Abstract][Full Text] [Related]
24. Exon 9 of the CFTR gene: splice site haplotypes and cystic fibrosis mutations.
Dörk T; Fislage R; Neumann T; Wulf B; Tümmler B
Hum Genet; 1994 Jan; 93(1):67-73. PubMed ID: 7505767
[TBL] [Abstract][Full Text] [Related]
25. A novel donor splice site characterized by CFTR mRNA analysis induces a new pseudo-exon in CF patients.
Costantino L; Claut L; Paracchini V; Coviello DA; Colombo C; Porcaro L; Capasso P; Zanardelli M; Pizzamiglio G; Degiorgio D; Seia M
J Cyst Fibros; 2010 Dec; 9(6):411-8. PubMed ID: 20875776
[TBL] [Abstract][Full Text] [Related]
26. Identification of novel mutations in Arabs with cystic fibrosis and their impact on the cystic fibrosis transmembrane regulator mutation detection rate in Arab populations.
Kambouris M; Banjar H; Moggari I; Nazer H; Al-Hamed M; Meyer BF
Eur J Pediatr; 2000 May; 159(5):303-9. PubMed ID: 10834512
[TBL] [Abstract][Full Text] [Related]
27. The role of common single-nucleotide polymorphisms on exon 9 and exon 12 skipping in nonmutated CFTR alleles.
Steiner B; Truninger K; Sanz J; Schaller A; Gallati S
Hum Mutat; 2004 Aug; 24(2):120-9. PubMed ID: 15241793
[TBL] [Abstract][Full Text] [Related]
28. Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR.
Zhang W; Zhang X; Zhang YH; Strokes DC; Naren AP
Drugs Today (Barc); 2016 Apr; 52(4):229-37. PubMed ID: 27252987
[TBL] [Abstract][Full Text] [Related]
29. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
[TBL] [Abstract][Full Text] [Related]
30. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
[TBL] [Abstract][Full Text] [Related]
31. mRNA-based detection of rare CFTR mutations improves genetic diagnosis of cystic fibrosis in populations with high genetic heterogeneity.
Felício V; Ramalho AS; Igreja S; Amaral MD
Clin Genet; 2017 Mar; 91(3):476-481. PubMed ID: 27174726
[TBL] [Abstract][Full Text] [Related]
32. Identification of mutations in exons 1 through 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Zielenski J; Bozon D; Kerem B; Markiewicz D; Durie P; Rommens JM; Tsui LC
Genomics; 1991 May; 10(1):229-35. PubMed ID: 1710599
[TBL] [Abstract][Full Text] [Related]
33. Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
McPhail GL; Clancy JP
Drugs Today (Barc); 2013 Apr; 49(4):253-60. PubMed ID: 23616952
[TBL] [Abstract][Full Text] [Related]
34. Alternative splicing of intron 23 of the human cystic fibrosis transmembrane conductance regulator gene resulting in a novel exon and transcript coding for a shortened intracytoplasmic C terminus.
Yoshimura K; Chu CS; Crystal RG
J Biol Chem; 1993 Jan; 268(1):686-90. PubMed ID: 7678008
[TBL] [Abstract][Full Text] [Related]
35. A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis.
Mickle JE; Macek M; Fulmer-Smentek SB; Egan MM; Schwiebert E; Guggino W; Moss R; Cutting GR
Hum Mol Genet; 1998 Apr; 7(4):729-35. PubMed ID: 9499426
[TBL] [Abstract][Full Text] [Related]
36. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
37. Targeted Integration of a Super-Exon into the CFTR Locus Leads to Functional Correction of a Cystic Fibrosis Cell Line Model.
Bednarski C; Tomczak K; Vom Hövel B; Weber WM; Cathomen T
PLoS One; 2016; 11(8):e0161072. PubMed ID: 27526025
[TBL] [Abstract][Full Text] [Related]
38. Two CFTR mutations within codon 970 differently impact on the chloride channel functionality.
Amato F; Scudieri P; Musante I; Tomati V; Caci E; Comegna M; Maietta S; Manzoni F; Di Lullo AM; De Wachter E; Vanderhelst E; Terlizzi V; Braggion C; Castaldo G; Galietta LJV
Hum Mutat; 2019 Jun; 40(6):742-748. PubMed ID: 30851139
[TBL] [Abstract][Full Text] [Related]
39. ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the Cystic Fibrosis Transmembrane Conductance Regulator Channel.
Wu YS; Jiang J; Ahmadi S; Lew A; Laselva O; Xia S; Bartlett C; Ip W; Wellhauser L; Ouyang H; Gonska T; Moraes TJ; Bear CE
Mol Pharmacol; 2019 Oct; 96(4):515-525. PubMed ID: 31427400
[TBL] [Abstract][Full Text] [Related]
40. A new era of personalized medicine for cystic fibrosis - at last!
Quon BS; Wilcox PG
Can Respir J; 2015; 22(5):257-60. PubMed ID: 26083544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
